Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study
2024

Correction of Data in Study on Romiplostim for Aplastic Anemia

Erratum

Author Information

Author(s): Mitani K, Lee JW, Jang JH

Primary Institution: The American Society of Hematology

Conclusion

This erratum corrects specific data in a previous publication regarding the efficacy and safety of romiplostim in refractory aplastic anemia.

Supporting Evidence

  • In supplemental Table 3, a correction was made for Patient #18's duration of platelet response.
  • In supplemental Figure 4, the label was corrected to reflect the number at risk.

Takeaway

This is a correction to a previous study, fixing some mistakes in the data presented.

Digital Object Identifier (DOI)

10.1182/bloodadvances.2024014868

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication